IFCC & EFLM

New EFLM webinar: Steam cells therapy and applications

By Dmitrii

Posted on August 31, 2021

EFLM e-learning

Darko Cerne, Chair of the EFLM WG Distance Education and e-Learning,
informs on next scheduled webinar and reminds that
the free access to EFLM webinars is reserved to EFLM Academy Members
(in order with the annual fee 2021)

Click here to know more about the EFLM Academy.

EFLM WEBINAR

Stem cells therapy and applications

14 September 2021

at h. 18.00 CET (duration 1 h)

Speaker: Yael Porat (IL)
Moderator: Dganit Itzhaky (IL)

Cilck here to register

The speaker will present a unique patented technology employing activated immune dendritic cells that specifically direct stem/progenitor cell therapeutic activity in-vitro which results in an enriched endothelial progenitor cells (EnEPCs; BGC101) product generated from a standard blood draw within a day. She will report long-term outcomes of a ” first in human “pilot study of BGC101 for treating patients with severe Critical Limb Ischemia (CLI) with no available surgical option.

Stem/progenitor cell treatments with bone-marrow-derived cells show promise in treating CLI, albeit not without adverse events related to cell mobilization and collection. As of 2020, 4 years after treatment, the therapy shows promising therapeutic effects in objective outcomes including limb salvage, increased leg blood flow and wound healing, as well as in walking ability, reduction of pain, decreased usage of narcotic medications and improved quality of life.

ABOUT THE SPEAKER :

Yael Porat, PhD, is founder and CEO of BioGenCell Ltd, a biotechnology company focusing on stem cell therapy and regenerative medicine. Dr. Porat earned her PhD in immunology from the Sackler School of Medicine, TelAviv University. Prior to founding BioGenCell, she served as head of the Global Biological Development Department at Teva Pharmaceuticals (NYSE: TEVA) and as CTO at TheraVitae, where she led the translation of innovative research into the production of stem cell based therapies used to treat patients with severe cardiovascular diseases.

BioGenCell is developing groundbreaking technology for automated production of patient-specific, blood-derived stem-cell-based therapies that enable physicians to treat patients the day after diagnosis. The company’s proprietary technology utilizes immune-directed stem-cell specific activity to create cell-based products for a wide range of diseases.

European Federation of Clinical Chemistry and Laboratory Medicine

Egmontstraat 11, Brussels
Belgium

ACCLMU

New EFLM webinar: Steam cells therapy and applications

Leave a Reply

Most Popular

Invitations to participate in a joint Congress and EFLM UEMS 21-24 September 2016 in Warsaw

Textbook “Clinical Biochemistry” 2013 Section 1

Proposal for publication of abstracts

Scientific & Practical Conference “Actual Issues of Laboratory Medicine”

Features of quality control of laboratory tests using test systems made by CJSC Vector-Best

Plenary lecture on June 21, 2015, at the IFCC Conference in Paris

Presentations at the Scientific & practical conference with international participation “DSTU EN ISO 15189:2015 – Roadmap to Quality of Laboratory Tests” (19-20 October 2016)

IFCC membership survey

The concept of implementation of ISO EN ISO 15189 into the practice of medical laboratories of Ukraine

Participation of the Association representatives in the IFCC General Conference